Published in Arthritis Rheum on October 01, 2001
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
A proposal for a worldwide definition of health resort medicine, balneology, medical hydrology and climatology. Int J Biometeorol (2010) 2.14
Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis (2005) 1.70
Hydrotherapy, balneotherapy, and spa treatment in pain management. Rheumatol Int (2004) 1.67
A brief history of spa therapy. Ann Rheum Dis (2002) 1.67
Conventional treatments for ankylosing spondylitis. Ann Rheum Dis (2002) 1.48
Radon therapy for the treatment of rheumatic diseases--review and meta-analysis of controlled clinical trials. Rheumatol Int (2003) 1.32
Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 1.26
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res (2002) 1.21
[Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]. Z Rheumatol (2006) 1.18
Balneotherapy in medicine: A review. Environ Health Prev Med (2005) 1.17
Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there? Rheumatol Int (2010) 1.14
Effect of combined spa-exercise therapy on circulating TGF-beta1 levels in patients with ankylosing spondylitis. Wien Klin Wochenschr (2006) 1.10
Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists. Ann Rheum Dis (2004) 1.07
Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis. Rheumatol Int (2005) 1.07
[Radon within therapeutic strategies of ankylosing spondylitis]. Wien Med Wochenschr (2008) 0.95
SPA therapy in fibromyalgia: a randomised controlled clinic study. Rheumatol Int (2005) 0.94
Long-term benefit of radon spa therapy in the rehabilitation of rheumatoid arthritis: a randomised, double-blinded trial. Rheumatol Int (2007) 0.94
Study of antioxidative effects and anti-inflammatory effects in mice due to low-dose X-irradiation or radon inhalation. J Radiat Res (2013) 0.94
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.7 Rehabilitation]. Z Rheumatol (2014) 0.89
Incidence of leukaemia and other malignant diseases following injections of the short-lived alpha-emitter 224Ra into man. Radiat Environ Biophys (2009) 0.89
The effects of combined spa therapy and rehabilitation on patients with ankylosing spondylitis being treated with TNF inhibitors. Rheumatol Int (2011) 0.89
Deposition of radon progeny on skin surfaces and resulting radiation doses in radon therapy. Radiat Environ Biophys (2010) 0.89
How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? Ann Rheum Dis (2007) 0.88
Therapeutic effect of spa therapy and short wave therapy in knee osteoarthritis: a randomized, single blind, controlled trial. Rheumatol Int (2006) 0.87
Effects of mud-bath treatment on fibromyalgia patients: a randomized clinical trial. Rheumatol Int (2007) 0.86
A 10-day course of SPA therapy is beneficial for people with severe knee osteoarthritis. A 24-week randomised, controlled pilot study. Clin Rheumatol (2007) 0.86
[Physiotherapeutic and rehabilitation therapy for ankylosing spondylitis. Status quo and are they still necessary in the age of anti-cytokine therapy?]. Z Rheumatol (2007) 0.85
Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. Clin Rheumatol (2008) 0.85
Exercise therapy for spondyloarthritis: a systematic review. Rheumatol Int (2014) 0.85
Effects of physical therapy for the management of patients with ankylosing spondylitis in the biological era. Clin Rheumatol (2014) 0.84
The effect of the thermal mineral water of Nagybaracska on patients with knee joint osteoarthritis--a double blind study. Clin Rheumatol (2006) 0.84
Long-term benefits of radon spa therapy in rheumatic diseases: results of the randomised, multi-centre IMuRa trial. Rheumatol Int (2013) 0.84
[Advice for patients diagnosed with ankylosing spondylitis: results of a representative patient survey in Germany]. Z Rheumatol (2011) 0.81
Radon treatment controversy. Dose Response (2006) 0.81
Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis. Health Qual Life Outcomes (2014) 0.81
The impact of serial radon and hyperthermia exposure in a therapeutic adit on pivotal cytokines of bone metabolism in rheumatoid arthritis and osteoarthritis. Clin Rheumatol (2016) 0.78
The treatment of the rheumatological manifestations of the inflammatory bowel diseases. Rheumatol Int (2006) 0.78
Successfully living with chronic arthritis. The role of the allied health professionals. Clin Rheumatol (2005) 0.78
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.3 Nonpharmaceutical therapeutic measures]. Z Rheumatol (2014) 0.78
Stanger bath therapy for ankylosing spondylitis: illusion or reality? Clin Rheumatol (2008) 0.78
Short term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice. BMC Res Notes (2013) 0.77
Has time come for a re-assessment of spa therapy? The NAIADE survey in Italy. Int J Biometeorol (2007) 0.77
Biopsychosocial determinants of physical and mental fatigue in patients with spondyloarthropathy. Rheumatol Int (2009) 0.76
Radon balneotherapy and physical activity for osteoporosis prevention: a randomized, placebo-controlled intervention study. Radiat Environ Biophys (2014) 0.76
Activation of Antioxidative Functions by Radon Inhalation Enhances the Mitigation Effects of Pregabalin on Chronic Constriction Injury-Induced Neuropathic Pain in Mice. Oxid Med Cell Longev (2015) 0.75
Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy. Core Evid (2008) 0.75
Management of ankylosing spondylitis with infliximab. Open Access Rheumatol (2009) 0.75
Decrease of Markers Related to Bone Erosion in Serum of Patients with Musculoskeletal Disorders after Serial Low-Dose Radon Spa Therapy. Front Immunol (2017) 0.75
Effect of spa therapy with saline balneotherapy on oxidant/antioxidant status in patients with rheumatoid arthritis: a single-blind randomized controlled trial. Int J Biometeorol (2016) 0.75
[Can the effects of radon therapy be scientifically substantiated?]. Wien Klin Wochenschr (2006) 0.75
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum (1984) 20.51
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum (1991) 11.66
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet (1997) 6.71
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum (2001) 4.57
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage (2004) 4.01
Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis (2004) 3.95
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis (2009) 3.15
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
How to diagnose axial spondyloarthritis early. Ann Rheum Dis (2004) 2.91
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis (2009) 2.76
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum (2008) 2.71
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.66
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis (2008) 2.61
Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis (2004) 2.60
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis (2003) 2.48
Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage (2000) 2.42
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 2.37
Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol (2014) 2.28
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol (1999) 2.21
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol (1999) 2.12
Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol (1997) 2.11
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis (2004) 2.08
Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis (2003) 2.03
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis (2002) 2.02
High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis (2007) 1.87
Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum (2002) 1.87
Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis (2005) 1.85
How Renoir coped with rheumatoid arthritis. BMJ (1998) 1.84
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81
Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis (2001) 1.77
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis (2008) 1.73
Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis (2005) 1.70
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum (2001) 1.68
A brief history of spa therapy. Ann Rheum Dis (2002) 1.67
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Smallest detectable difference in radiological progression. J Rheumatol (1999) 1.64
Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up. Ann Rheum Dis (2008) 1.60
Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis (2005) 1.59
Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis (2004) 1.56
The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol (1997) 1.55
Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol (1999) 1.54
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
[Various opinions of family physicians and rheumatologists about the management of patients with rheumatoid arthritis]. Ned Tijdschr Geneeskd (1996) 1.52
Quality of life in rheumatoid arthritis. Br J Rheumatol (1997) 1.52
Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis (2005) 1.51
Comparing morphometric X-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. Rheumatology (Oxford) (2007) 1.49
Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis (2004) 1.49
Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality? Ann Rheum Dis (2003) 1.46
Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis (2008) 1.44
Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin Rheumatol (2002) 1.44
Increased plasma endothelin-1 levels in fibromyalgia syndrome. Rheumatology (Oxford) (2003) 1.44
The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum (1995) 1.44
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis (2007) 1.44
High positive predictive value of specific antibodies cross-reacting with a 28-kDa Drosophila antigen for diagnosis of ankylosing spondylitis. Rheumatology (Oxford) (2005) 1.41